Last week, the House passed a Pelosi-backed prescription drug bill that would allow Medicare to negotiate with pharmaceutical companies for lower prices.
If signed into law, H.R.3 would also establish a $2,000/year cap on out of pocket costs for Medicare patients and require drugmakers to pay rebates if their drug prices rise faster...Arizona News
The pharmaceutical companies on Capitol Hill rarely get the short-end of the stick, so it shouldn't come as a surprise that the industry is lobbying for a provision to block the increase of the percentage of drug costs they must cover under Medicare.
Lawmakers are now considering to add measures that would ease the burden of drug...
